Advertisement · 728 × 90
#
Hashtag
#PediatricObesity
Advertisement · 728 × 90
Preview
Personal Activity Trackers and Family Engagement in a Pediatric Obesity Intervention: Randomized Controlled Trial Background: Pediatric obesity continues to be a national health crisis. Parents play a critical role in obesity interventions. Digital health interventions, like personal activity trackers (PATs), can help better engage parents in pediatric obesity interventions and improve outcomes. Objective: 1) Assess the #feasibility and acceptability of implementing personal activity trackers as part of a comprehensive family-based lifestyle intervention for pediatric obesity (BodyWorks) in a federally qualified health center. 2) Evaluate the impact of personal activity trackers on parents on child anthropometrics and the overall program. 3) Examine the associations between steps/day and usage (minutes) with body composition outcomes. Methods: : In this randomized controlled trial, 158 families were randomized to receive the BodyWorks (BW) curriculum alone (control) or BW plus a PAT for the parent (intervention). Data were collected at baseline and post-intervention (8 weeks). Child weight outcomes, including BMI, BMI z-score, and BMI percent of the 95th percentile (%BMIp95), were compared using generalized estimating equations. Parent and child PAT usage was analyzed with multivariable models Results: There were no baseline differences between groups. After adjustment, children in the intervention group had significantly greater reductions in BMI z-score compared to controls (–0.035 vs –0.001; p for interaction = 0.009). There were no significant differences in %BMIp95. Among intervention participants, each 1,000-step increase per day was associated with a 0.009 increase in BMI z-score (p = 0.005). Most parents reported high satisfaction with PATs; 95% agreed or strongly agreed that devices were easy to use and motivating Conclusions: PATs are feasible and acceptable tools for engaging families in pediatric obesity programs. While short-term weight outcomes showed modest benefit, further research is needed to assess clinical significance and long-term effects. Digital health tools may enhance engagement in low-resource settings without exacerbating the digital divide. Clinical Trial: ClinicalTrials.gov NCT03215641; https://clinicaltrials.gov/study/NCT03215641

JMIR Formative Res: Personal Activity Trackers and Family Engagement in a Pediatric Obesity Intervention: Randomized Controlled Trial #PediatricObesity #FamilyEngagement #DigitalHealth #ActivityTrackers #HealthyFamilies

0 0 0 0
Post image

A new study finds children and teens with obesity or diabetes who take GLP-1 weight-loss medications experience significant improvements in many cardiometabolic risk factors, but long-term safety questions remain.

youtu.be/YVMGmi4CfXs

#GLP1 #ChildHealth #TeenHealth #PediatricObesity #GLP1Drugs

0 0 0 0
Post image

Vitamin D Supplementation Reduces Hyperlipidemia and Improves Bone Mass in Pediatric Obesity

www.dl.begellhouse.com/journals/2ff...

#PediatricObesity #VitaminDSupplementation #MetabolicSyndrome

0 0 0 0
Preview
Weighing the future: strategic measures against rising childhood obesity - Pediatric Research Pediatric Research - Weighing the future: strategic measures against rising childhood obesity

Weighing the future: strategic measures against rising childhood obesity

#PediatricObesity

1 0 0 0
Post image

Body mass index triples overweight prevalence in 7600 children compared with waist-to-height ratio: the ALSPAC study by Andrew O Agbaje

Volume 1, Issue 1, January 2025
Open access paper 👉 doi.org/10.1093/oben...

#endocrinology #pediatricobesity #T2D #adolescentobesity

1 2 0 0
Box and injection pen of Saxenda (liraglutide) 6 mg/mL, a prescription medication used for weight management. The pen is light blue with dosage markings, placed in front of the product packaging. Image courtesy of Novo Nordisk.

Box and injection pen of Saxenda (liraglutide) 6 mg/mL, a prescription medication used for weight management. The pen is light blue with dosage markings, placed in front of the product packaging. Image courtesy of Novo Nordisk.

Liraglutide reduced BMI by 5.8% in children aged 6–11 with obesity in the SCALE Kids trial. However, side effects and long-term outcomes require further study.

jcst2d.com/index.php?vi...

#Liraglutide #ChildhoodObesity #SCALEKids #GLP1 #PediatricObesity

0 0 0 0

🔗jamanetwork.com/journals/jamanetworkopen...

#chilhoodobesity #pediatricobesity #health #foodishealth

0 0 0 0
Post image Post image

📃New #EDENcohort article by @BarbaraHeude and colleagues published in #PediatricObesity. As early as infancy higher energy intake and greater appetite mediate part of the relationship between genetic susceptibility to obesity and childhood BMI. 🍽️Here:

onlinelibrary.wiley.com/doi/abs/10.111…

0 0 0 0